Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria

Pediatric Infectious Disease Journal

Volumn 31, Issue 1, 2012, Pages

  Resch, Bernhard ^a   Sommer, Constanze ^a   Nuijten, Mark J C ^b   Seidinger, Susanne ^c   Walter, Evelyn ^d   Schoellbauer, Vera ^d   Mueller, Wilhelm D ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Ars Accessus Medica   (Netherlands)

^c ABBOTT LABORATORIES   (United States)

^d Institute for Pharmacoeconomic Research   (Austria)

Author keywords

cost effectiveness; epidemiology; palivizumab; premature infant; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; AUSTRIA; CHILD; CHILDHOOD DISEASE; CONGENITAL HEART BLOCK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FOLLOW UP; GESTATIONAL AGE; HEALTH CARE SYSTEM; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PEDIATRICS; PREMATURITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRIA; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RISK; TREATMENT OUTCOME;

EID: 84855442866     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318235455b     Document Type: Article

References (47)

1. Hall CB, Weinberg G, Iwane M, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-5988.
2. Garcia C, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non RSV bronchiolitis. Pediatrics. 2010;126:1453-1460.
3. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-1928. (Pubitemid 32553362)
4. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory-syncytial virus. Am J Dis Child. 1986;140:543-546. (Pubitemid 16120909)
5. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045-1052.
6. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102: 531-537.
7. Feltes T, Cabalka A, Meissner H, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytical virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540. (Pubitemid 37352516)
8. Austrian SmPC Synagis. Available at: http://www.emea.europa.eu.
9. Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Rev Pharmaecon Outcomes Res. 2007;7:445-458. (Pubitemid 350120039)
10. Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res. 2008;8:529-538.
11. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007;25:55-71. (Pubitemid 46072368)
12. Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr. 2010;157:209-214.
13. Paramore LC, Mahadevia PJ, Piedra PA. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr Pulmonol. 2010;45:578-584.
14. Resch B, Gusenleitner W, Nuijten M, et al. Cost-effectiveness of palivizumab against respiratory syncytial virus infection in high-risk children in Austria. Clin Ther. 2008;30:749-760. (Pubitemid 351680486)
15. Clinical Trials Number NCT01077271. Compliance to Synagis (Palivizumab) Under Daily Pediatrician's Conditions in Premature Infants 33-35 wGA. Available at: http://clinicaltrials.gov/ct2/results?term-NCT01077271.
16. RSV Hotline Austria. Available at: https://hc4you.hcsolutions.at/rsv/. 2010.
17. Resch B, Gusenleitner W, Müller WD, et al. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis. 2006;25:120-122. (Pubitemid 43333675)
18. Raith W, Sommer C, Kurath S, et al. Seasonal variability of respiratory syncytial virus infections in Austria: a 16 years analysis. In: Global Expert Meeting; 2009; (Dublin): Ireland.
19. Walter E. Ö sterreichische Guidelines zur gesundheitsö konomischen Evaluation. Pharmacoecon Ger Res Artic. 2006;4:55-63.
20. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95:500-505.
21. Sigurs N, Bjarnson R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501-1507. (Pubitemid 30329018)
22. Sigurs N, Gustafsson PM, Bjarnson R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137-141. (Pubitemid 40105412)
23. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89:673-678.
24. WirtschaftskammerÖ sterreich. Available at: http://wko.at/statistik/ eu/eubip. htm. 2010.
25. Statistik Austria. Lebenserwartung in Gesundheit, 2005. Available at: http://www.statistik.at/web-de/index.html.
26. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:150-156.
27. Warenverzeichnis I. Arzneispezialitäten und Mittel gemäß Gesamtvertrag Anlagen II und III. Ö sterreichischer Apothekerverlag, Jänner 2010.
28. Oberösterreichische Gebietskrankenkasse (OÖ GKK). Arbeitsbehelf Honorarordnung fürÄ rzte für Allgemeinmedizin und Fachärzte, 7. Available at: http://www.ooegkk.at/.
29. Niederösterreichische Gebietskrankenkasse (NÖ GKK). Honorarordnung für Ä rzte für Allgemeinmedizin und Fachärzte. 2006. Available at: http://cms.arztnoe.at/cms/beitrag/.
30. Steiermärkische Gebietskrankenkasse (STGKK). Satzung 2007der Steierma ̈rkischen Gebietskrankenkasse. 2003. Available at: www.stgkk.at/.
31. Tiroler Gebietskrankenkasse (TGKK). Honorarordnung für Ä rzte für Allgemeinmedizin und Fachärzte. 2008. Available at: https://www.sozialversicherung.at/.
32. Wiener Gebietskrankenkasse (WGKK). Tarife für Vertragsärzte. 2009.
33. Von der Schulenburg JM, Greiner W, Molitor S, et al. Kosten der Asthmatherapie nach Schweregrad Eine empirische Untersuchung. Med Klin (Munich). 1996;91:670-676. (Pubitemid 26361314)
34. Statistik Austria. Bruttojahreseinkommen. 2007.
35. Resch B, Berger A, Eber E, et al. Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und post-RSV-atemwegserkrankung. Monatsschr Kinderheilkd. 2008;156:381-383.
36. Stewart DL, Romero JR, Buysman EK, et al. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin. 2009;25:2795-2804.
37. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(suppl 5):S133-S141. (Pubitemid 37456911)
38. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104: 419-427. (Pubitemid 29424659)
39. Robbins JM, Tilford JM, Jacobs RF, et al. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366. (Pubitemid 28193296)
40. Forbes ML, Hall CB, Jackson A. Cost and resource utilization of respiratory syncytial virus (RSV) or winter unspecified bronchiolitis or pneumonia (UBP) hospitalizations during the first year of life among late preterm and full-term infants. Poster presented at: ISPOR 14th Annual International Meeting; May 16-20, 2009; Orlando, FL.
41. Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16:46-58.
42. Rietveld E, Steyerberg EW, Polder JJ, et al. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis. Arch Dis Child. 2010;95:493-498.
43. Bont L, Ramilo O. The relationship between RSV bronchiolitis and recurrent wheeze: the chicken and the egg. Early Hum Dev. 2011;87(suppl 1):S51-S54.
44. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11:105-115.
45. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160:1070-1076. (Pubitemid 44520638)
46. Neovius K, Buesch K, Sandström K, et al. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. doi: 10.1111/j.1651-2227.2011.02309.x.
47. Hampp C, Kauf TL, Saidi AS, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165:498-505.